Poxel S.A.
EPA:POXEL.PA
0.53 (EUR) • At close September 18, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Poxel S.A. |
Symbool | POXEL.PA |
Munteenheid | EUR |
Prijs | 0.53 |
Beurswaarde | 28,052,455 |
Dividendpercentage | 0% |
52-weken bereik | 0.297 - 0.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D. |
Website | https://www.poxelpharma.com |
An error occurred while fetching data.
Over Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)